Prelude Therapeutics (PRLD) Total Current Liabilities (2019 - 2026)

Prelude Therapeutics has disclosed Total Current Liabilities across 8 years of filings, most recently posting $41.7 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $41.7 million, up 110.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.7 million (up 110.85% YoY), and the FY2025 annual result was $53.0 million, up 106.68% from the prior year.
• Total Current Liabilities came in at $41.7 million for Q1 2026 at Prelude Therapeutics, down from $53.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $53.0 million in Q4 2025 to a low of $15.2 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $20.9 million (2025), against an average of $23.0 million.
• Across the five-year window, Total Current Liabilities decreased 21.65% in 2023 and soared 110.85% in 2026, its largest moves.
• Prelude Therapeutics' Total Current Liabilities stood at $21.7 million in 2022, then gained by 0.59% to $21.8 million in 2023, then gained by 17.46% to $25.6 million in 2024, then jumped by 106.68% to $53.0 million in 2025, then fell by 21.27% to $41.7 million in 2026.
• The last three Total Current Liabilities figures came in at $41.7 million (Q1 2026), $53.0 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.